Bristol-Myers (BMY), Pfizer (PFE) See $5B of Market Cap Evaporate Following CRL on ELIQUIS
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Join SI Premium – FREE
Shares of Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) are getting hit following earlier news the FDA issued a Complete Response Letter for the New Drug Application for ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The CRL said more information would be needed on data management and verification from the ARISTOTLE trial.
While overall market pressure is certainly playing a key role, Bristol shares are down 3.6 percent while shares of Pfizer -- which never move -- are off 1.7 percent. Total market cap lost is roughly $5 billion in the morning session.
While overall market pressure is certainly playing a key role, Bristol shares are down 3.6 percent while shares of Pfizer -- which never move -- are off 1.7 percent. Total market cap lost is roughly $5 billion in the morning session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Cytek faces $56M damages award in Beckman Coulter patent case
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate News, FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
